Colorectal cancer (CRC) is the third most prevalent cancer and the fourth most common cause of cancer mortality worldwide[@b1]. Accumulating epidemiological studies suggest that high vitamin D intake may influence the risk of CRC[@b2][@b3], which is an interesting cancer prevention strategy that has raised public concerns globally. Although vitamin D can be obtained from diet and dietary supplements, most vitamin D is synthesized by human skin exposed to the sunlight. Due to reduced outdoor activity, the absence of adequate sun exposure and limited resource of vitamin D supplements from diet, vitamin D deficiency is a common phenomenon both in healthy individuals and in CRC cases[@b4].

25-hydroxyvitamin D (25(OH)D), the precursor of the active form of vitamin D, is recognized as the optimal indicator of vitamin D metabolic status with a relatively long half-life and high concentration in plasma[@b5]. 25(OH)D is commonly bound to vitamin D binding protein (VDBP) and albumin(Alb), which can be converted into hormonally active 1,25-dihydroxyvitamin D3 (1,25(OH)~2~D3) in the kidney, colon and several other tissues[@b6][@b7][@b8][@b9]. The majority of 25(OH)D and 1,25(OH)~2~D3 are primarily bound to VDBP, approximately 10--15% to Alb, free 25(OH)D and 1,25(OH)~2~D3 only account for less than 1%[@b10]. Since the affinity of Alb to 25(OH) D or 1,25(OH)~2~D3 is weaker than that of VDBP, the loosely binding fraction and the free fraction consist of bioavailable 25(OH)D[@b11]. Vitamin D receptor (VDR), a key nuclear receptor, can only be activated by the free form of 1,25(OH)~2~D3, and regulates the transcription and expression of numerous vitamin D targeted genes that are related to cell proliferation, differentiation, invasion and angiogenesis.

VDBP, which is synthesized and secreted primarily by the liver, includes three functional domains. Although 25(OH)D and 1,25(OH)~2~D3 are mainly bound to VDBP domain I, circulating VDBP and Alb levels considerably exceed the concentrations of 25 (OH)D and 1,25(OH)~2~D3[@b12]. VDBP also plays an important role in the elimination of dead or injured cell, macrophage activation and neutrophil chemotaxis in inflammatory condition[@b12]. As inflammation is deemed to be an important contributor to carcinogenesis, while inflammatory-cells such as macrophage and neutrophil are the main components to defense against cancer cell[@b13], we thus speculate that VDBP may be involved in carcinogenesis and cancer progression.

Recently, several studies have reported the relationship among VDBP, 25(OH)D and the risk of cancer. Two studies showed that circulating VDBP was inversely associated with the risk of pancreatic cancer and renal cell carcinoma[@b14][@b15]. Another study reported no association between VDBP and bladder cancer[@b16]. In addition, study by Stephanie et al[@b17] indicated that VDBP might modulate the impact of vitamin D status on prostate cancer. However, there is no study reporting the influence of VDBP on the association between circulating total, free, and bioavailable 25(OH)D and the risk of CRC. Therefore, in this study, we measured the circulating VDBP, total, free and bioavailable 25(OH)D in 212 CRC patients and 212 well-matched healthy controls and further explored the relationship between total, free, bioavailable 25(OH)D and VDBP, and the risk of CRC.

Methods
=======

All subjects in our study were from a health assessment cohort population in Nanjing First Hospital (Nanjing, Jiangsu, China). The health assessment cohort population comprised 25616 routine physical examination of individuals who performed annually in Nanjing First Hospital from 2010 to 2012. All participants were healthy, cancer-free individuals, didn′t show clinical CRC symptoms, rectal digital examination and fecal occult blood test were normal and tumor protein biomarkers (plasma CEA, CA199, CA50 and CA242) were lower than the reference values when they were enrolled in the cohort, with an average follow-up time of 3.4 years until diagnosis. The case group consisted of 212 CRC patients, including 115 colon and 97 rectal cancer patients, and ranging in age from 37 to 83 years. All CRC patients were all initially diagnosed by colonoscopy and CT detections, and confirmed with histological evidence from biopsies performed from 2013 to 2014 in Nanjing First Hospital. Patients with acute or chronic renal and liver failures, nutritional problem (malnutrition, anemia, hypoproteinemia, anorexia and inappetence), active infection, or without histological confirmation were excluded from the present study. The controls were composed of 212 blood collections from healthy individuals with matched gender, age (±5 year) and blood collection time. Due to unwillingness of the controls and its invasiveness, colonoscopy was not used to exclude the CRC in the controls. However, all the controls were clinical symptom-free of CRC, rectal digital examination, fecal occult blood test and tumor protein biomarkers (plasma CEA, CA199, CA50 and CA242) were normal. All participants enrolled in our study did not use vitamin D or calcium supplement and drugs that might influence circulating calcium, phosphorus and 25(OH)D concentrations in recent six months. Relative clinical data were obtained from the hospital medical record. Blood samples of enrolled subjects in our study were collected during the first time health check-up in Nanjing First Hospital between November and February from 2010 to 2012. Samples were drawn between 8:00 and 10:00 each morning, and plasma samples were stored at -80 °C until measurement. This study was approved by the Institution Ethics Commission of Southeast University, written informed consents were obtained from all participants and the methods were carried out in accordance with the approved guidelines.

Plasma total 25(OH)D concentration were measured by direct competitive enzyme-linked immunosorbent assay using 25(OH) D immunoassay kit (HCB Ltd, Vancouver, Canada) with the coefficient of variations of inter- and intra-batch to be 9.0% and 9.0%, respectively. Measurement of circulating plasma VDBP concentration was carried out using human vitamin D binding protein immunoassay kit (R&D Systems, Minneapolis, USA) according to the manufacturer\'s protocol. The inter- and intra-batch of the kit were 10.8% and 15.2%, respectively. Blinded quality controlled samples were included in each batch, and all the measurements were conducted in triplicate in all plasma samples. Plasma Alb concentration was measured by Beckman automatic biochemical analyzer (AU680) (Beckman Coulter lnc, Tokyo, Japan) using a bromocresol green dye assay. Applying the mathematical equations provided by Bhan et al[@b18], free and bioavailable 25(OH)D were calculated based on the concentrations of plasma Alb, total 25(OH) D and VDBP. All measurements were carried out in April of 2014.

Descriptive statistics for baseline characteristics were calculated with the median and quartile for continuous variables or frequencies for categorical variables. Quartile cut-points for VDBP, total, free and bioavailable 25(OH)D were determined based on the distribution among controls. The trend across categories by modeling the median of each category as a continuous variable and Wald test was used to evaluate its statistical significance. Conditional logistic regression was used to estimate the odds ratio(OR) and 95% confidence interval (CI) of CRC by the quartiles of VDBP, total, free and bioavailable 25(OH)D. Factors which may influence plasma 25(OH)D, VDBP, or the risk of CRC were included in the multivariable logistic regression models. Therefore, multivariable model was adjusted for the matching factors (sex and age), body mass index (BMI), and the status of smoking, drinking, diabetes and hypertension. Moreover, the results were mutually adjusted for 25(OH)D or VDBP. We also analyzed the stratifying total, free and bioavailable 25(OH)D by VDBP (\<median vs. ≥median) and VDBP by 25(OH)D (\<median vs. ≥median) using unconditional logistic regression. Likehood ratio test was applied to assess statistical interaction in the multivariable-adjusted model. All these statistical calculations were performed using SPSS 17.0 software (SPSS Inc, Chicago, USA) and a *p*-value \< 0.05 was recognized as statistically significance in all calculations.

Results
=======

A total of 424 individuals including 212 newly diagnosed CRC patients and 212 healthy participants matched with gender and age (±5 year) as well as blood collection time were enrolled in this study. Baseline characteristics of cases and controls were described in [Table 1](#t1){ref-type="table"}. No significant difference was found in BMI value, frequencies of smoking, drinking, diabetes and hypertension as well as concentration of circulating VDBP when compared with two groups. However, the plasma total, free and bioavailable 25(OH)D in CRC cases were significantly lower in comparison with the controls (*p*-value \< 0.001, = 0.018 and 0.001).

The results of associations among plasma VDBP, total, free and bioavailable 25(OH) D and the risk of CRC were listed in [Table 2](#t2){ref-type="table"}. Plasma VDBP concentration was not observed to be directly associated with the risk of CRC, further adjustment for 25(OH)D did not alter the quartile risk estimates (*p*-trend = 0.944, OR = 0.93, 95%CI = 0.51--1.69 for Q4:Q1). Adjustment for VDBP did not alter the inverse association between plasma total 25(OH)D and the risk of CRC (*p*-trend = 0.027, OR = 0.53, 95%CI = 0.29--0.98 for Q4:Q1). Moreover, negative associations were also observed between free 25(OH)D (*p*-trend \< 0.001, OR = 0.42, 95%CI = 0.22--0.82 for Q4: Q1), bioavailable 25(OH)D (*p*-trend = 0.006, OR = 0.29, 95%CI = 0.15--0.56 for Q4: Q1) and the risk of CRC. No significant risk association was found between VDBP and CRC stratifying by 25(OH)D (*p*-interaction = 0.280, *p*-trend = 0.490, OR = 0.72, 95%CI = 0.33--1.57). On the contrary, plasma VDBP modified the association between total, free and bioavailable 25(OH)D and CRC, with lower risk for elevated total, free and bioavailable 25(OH)D appeared to be restricted to individuals with lower concentrations of VDBP (total 25(OH)D Q4:Q1 *p*-interaction = 0.001, *p*-trend \< 0.001, OR = 0.14, 95%CI = 0.05--0.41; free 25(OH)D Q4:Q1 *p*-interaction = 0.001, *p*-trend \< 0.001, OR = 0.10, 95%CI = 0.04--0.22; bioavailable 25(OH)D Q4:Q1 *p*-interaction = 0.001, *p*-trend \< 0.001, OR = 0.03, 95%CI = 0.01--0.08) ([Table 3](#t3){ref-type="table"}).

Discussion
==========

In this study, we found strong inverse associations between total, free and bioavailable 25(OH)D and the risk of CRC. However, we did not find a direct association between circulating VDBP and the risk of CRC. Interestingly, higher circulating total, free and bioavailable 25(OH)D concentrations were inversely associated with CRC only when circulating VDBP below the median. Our results suggest that higher VDBP level may sequester more 25(OH)D leading to less free and bioavailable 25(OH)D, and free and bioavailable 25(OH)D may be more biologically relevant to the risk of CRC in comparison with total 25(OH)D.

VDBP, a glycosylated-globulin, plays an important role not only in transporting vitamin D and circulating metabolites, but also in other biological functions to affect carcinogenesis. It is a member of the circulating actin scavenger system that prevents formation of F-actin networks and harmful effects following from cell or tissue damage[@b12]. VDBP is involved in macrophage activation by converting as group-specific component protein derived macrophage activating factor (GcMAF) and neutrophil chemotaxis by enhancing the chemotactic effect of complement-derived peptides[@b19]. Several studies have investigated the association between plasma VDBP and cancer risk, including bladder, prostate and colorectal cancers[@b16][@b17][@b20][@b21]. A recent study conducted by Anic et al[@b20] reported that circulating VDBP was not associated with CRC risk, but found positive associations between 25(OH)D, the 25(OH)D:DBP molar ratio and CRC among men with higher VDBP concentration. Another study reported by Weinstein et al[@b21] indicated that circulating 25(OH)D was inversely associated with CRC and DBP did not modify the association between 25(OH)D and CRC. Consistent with these studies, our results did not conclude that VDBP was associated with CRC, but low levels of total, free and bioavailable 25(OH)D were associated with elevated CRC risk, whereas the negative associations between total, free, bioavailable 25(OH)D and CRC were found only when individual with lower level of VDBP (\<median). These findings indicate that VDBP is not involved in colorectal carcinogenesis through such mechanisms, but support the "free hormone hypothesis" that lower concentration of VDBP may bind less 25(OH)D contributing to higher level of circulating free and bioavailable 25(OH)D, while free and bioavailable 25(OH)D have more biological effects on colorectal tissue. It has been reported that 1,25(OH)~2~D3 and its analogues could inhibit growth and promote apoptosis, proliferation and differentiation of colon cancer cell in a dose-dependent manner[@b22][@b23]. 25(OH)D can be transformed into 1,25(OH)2D3 in colon tissue, and bioavailable 25(OH)D may be taken up into colorectal cells via diffusion across cell membranes, or via endocytosis of bound to VDBP by interaction of VDBP with megalin and cubulin[@b24][@b25]. The metabolite of 1,25(OH)~2~D3 binds to VDR is expressed in colorectal cell and forms a 1,25(OH)~2~D3-VDR complex to regulate a series of genes that are involved in colorectal carcinogenesis[@b26][@b27]. Moreover, VDBP may only have its canonical role in transporting 25(OH)D, not directly relating to colorectal carcinogenesis. Furthermore, previous studies have indicated that VDBP was markedly deglycosylated in CRC patients[@b28]. A higher level of deglycosylated VDBP results in a lower level of GcMAF. Consequently, eliminated GcMAF cannot perform its biological activities to macrophages and phagocytic activation, anti-angiogenesis effect and antitumor activity[@b29][@b30][@b31][@b32][@b33]. In addition, more than 120 single nucleotide polymorphisms were identified in VDBP gene, rs7041 and rs4588 has been demonstrated to influence the affinity of VDBP for VD and were associated with the concentration of 25(OH)D, VDBP who carried allele C of rs4588 has been illustrated to be less able to convert as GcMAF[@b34][@b35]. Therefore, genetic variation of VDBP gene may affect its secondary construction and function, eliminating its functions of antitumorigenesis.

To our knowledge, it is the first investigation studying the association of plasma VDBP, free and bioavailable 25(OH)D with the risk of CRC. Our prospective measurement of circulating VDBP, Alb, 25(OH)D to assess the association of VDBP, total, free and bioavailable 25(OH)D with CRC risk is a strength of our study. Moreover, all plasma samples were collected between 8:00 and 10:00 each morning in winter season in Nanjing first hospital, which could maximize reduce the influence from sunlight, intensity of ultraviolet ray, and diurnal and postprandial fluctuations. However, several limitations of this study should be addressed. Due to limited available plasma samples, small sample size of our study could not represented the whole population and would reduce statistical power in our study. Although VDBP was supposed to be stable in adulthood[@b36], each plasma sample of the individual was only collected and measured at one point, which could not reflect the comprehensive status of total circulating vitamin D and DBP in all participants. Furthermore, we did not obtain detailed information concerning multiple potential confounding factors of each participant, such as physical activity, dietary vitamin intake and exposure to sunshine.

In summary, although we did not observe a direct association between VDBP and the risk of CRC, high levels of circulating total, free, bioavailable 25(OH)D were associated with a decreased risk of CRC, particularly when VDBP concentration was below the median. These findings suggest that VDBP is just a VD transporter which may not affect colorectal carcinogenesis, but can modulate the impact of vitamin D status on CRC. Thus the simultaneous detection and investigation of plasma total, free, bioavailable 25(OH)D and VDBP may be important for studying the relationship between vitamin D and the risk of CRC.
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###### Baseline characteristics of colorectal cancer patients and controls[a](#t1-fn1){ref-type="fn"}

  Characteristics                                 Cases (n = 212)[a](#t1-fn1){ref-type="fn"}   Controls (n = 212)[a](#t1-fn1){ref-type="fn"}   *p*-value[b](#t1-fn2){ref-type="fn"}
  ----------------------------- ---------------- -------------------------------------------- ----------------------------------------------- --------------------------------------
  Age,                           Median (range)                   63(56--73)                                    63(57--73)                                    0.958
  BMI (kg/m^2^)                  Median (range)                22.6(20.8--23.8)                              23.2(22.0--24.4)                                 0.122
  Smoking, n (%)                      Yes                         50 (23.6%)                                    64 (30.2%)                                    0.125
                                       No                        162 (76.4%)                                    148 (69.8%)                                      
  Drinking, n (%)                     Yes                         25 (11.8%)                                    33 (15.6%)                                    0.258
                                       No                        187 (88.2%)                                    179 (84.4%)                                      
  Diabetes, n (%)                     Yes                         31 (14.6%)                                    24 (11.3%)                                    0.312
                                       No                        181 (85.4%)                                    188 (88.7%)                                      
  Hypertension, n (%)                 Yes                         47 (22.2%)                                    39 (18.4%)                                    0.334
                                       No                        165 (77.8%)                                    173 (81.6%)                                      
  Plasma VDBP                       (ug/ml)                212.27 (168.59--285.60)                        215.74 (172.36--288.15)                             0.271
  Plasma 25(OH)D                    (ng/ml)                   9.71 (5.70--17.73)                            14.6 (7.28--28.84)                               \<0.001
  Plasma free 25(OH)D               (pg/ml)                  0.022 (0.013--0.042)                          0.033 (0.014--0.062)                               0.018
  Plasma bioavailable 25(OH)D       (pg/ml)                   1.25 (0.72--2.57)                              2.02 (0.88--3.69)                                0.001

^a^Values are medians (interquartile range) or proportions.

^b^χ^2^ test for categorical variables and Wilcoxon signed rank test for continuous variable.

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; VDBP, vitamin D binding protein.

###### Odds ratios and 95% confidence interval for the association of plasma VDBP, total, free and bioavailable 25(OH)D with the risk of colorectal cancer

                                            Quartile 1       Quartile2            Quartile3           Quartile4       *p*-trend
  ---------------------------------------- ------------ -------------------- -------------------- ------------------ -----------
  VDBP, range (ug/ml)                        \<168.59    168.59 -- \<212.27   212.27 -- \<285.60       ≥285.60             
  No. of cases/no. of controls                64/53            48/53                49/53               51/53              
  OR[a](#t2-fn1){ref-type="fn"} (95%CI)         1         0.79(0.46--1.38)     0.75(0.44--1.30)    0.78(0.45--1.35)     0.569
  OR[b](#t2-fn2){ref-type="fn"} (95%CI)         1         0.82(0.71--0.95)     0.77(0.44--1.34)    0.83(0.47--1.46)     0.615
  OR[c](#t2-fn3){ref-type="fn"}(95%CI)          1         1.48(0.77--2.85)     0.95(0.53--1.69)    0.93(0.51--1.69)     0.944
  Total 25(OH)D, range (ng/ml)                \<7.29      7.29 -- \<14.61      14.61 -- \<28.84         ≥28.84             
  No. of cases/ no. of controls               80/53            49/53                46/53               37/53              
  OR[a](#t2-fn1){ref-type="fn"}(95%CI)          1         0.65(0.38--1.11)     0.62(0.36--1.07)    0.47(0.27--0.84)     0.007
  OR [b](#t2-fn2){ref-type="fn"}(95%CI)         1         0.67(0.39--1.16)     0.63(0.36--1.09)    0.44(0.24--0.79)     0.006
  OR [c](#t2-fn3){ref-type="fn"} (95%CI)        1         0.62(0.35--1.12)     0.67(0.38--1.20)    0.53(0.29--0.98)     0.027
  Free 25(OH)D, rang (pg/ml)                 \<0.0136    0.0136 -- \<0.0329   0.0329 -- \<0.062         ≥0.062             
  No. of cases/ no. of control                58/53            82/53                49/53               23/53              
  OR [a](#t2-fn1){ref-type="fn"} (95%CI)        1         1.42(0.84--2.42)     0.91(0.52--1.58)    0.42(0.22--0.79)    \<0.001
  OR[b](#t2-fn2){ref-type="fn"} (95%CI)         1         1.51(0.88--2.57)     0.91(0.52--1.60)    0.42(0.22--0.82)    \<0.001
  Bioavailable 25(OH)D, rang (pg/ml)          \<0.88       0.88 -- \<2.02       2.02 -- \<3.69          ≥3.69              
  No. of cases/ no. of controls               73/53            59/53                60/53               20/53              
  OR[a](#t2-fn1){ref-type="fn"} (95%CI)         1         0.84(0.49--143)      0.84(0.49--1.42)    0.30(0.16--0.56)     0.007
  OR[b](#t2-fn2){ref-type="fn"} (95%CI)         1         0.93(0.54--1.60)     0.84(0.49--1.44)    0.29(0.15--0.56)     0.006

^a^Conditioned on age and gender.

^b^Condition on age and gender, and adjusted for BMI, smoking, drinking, history of diabetes and hypertension.

^c^Condition on age and gender, and adjusted for BMI, smoking, drinking, history of diabetes and hypertension as well as either total 25(OH)D or VDBP.

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; OR, odds ratio; VDBP, vitamin D binding protein.

###### Odds ratios and 95% confidence interval for the association between plasma VDBP stratifying by total 25 (OH)D or total, free and bioavailable 25 (OH)D stratifying by VDBP and the risk of colorectal cancer

                                            Quartile1       Quartile2            Quartile3           Quartile4       *p*-trend   *p*-interaction
  ---------------------------------------- ----------- -------------------- -------------------- ------------------ ----------- -----------------
  VDBP, range (ug/ml)                       \<168.59    168.59 -- \<212.27   212.27 -- \<285.60       ≥285.60                            
  25(OH)D above median                                                                                                                   
  No. of cases/no. of controls                10/19           28/37                20/25               25/25                             
  OR[a](#t3-fn1){ref-type="fn"}(95%CI)          1        1.63(0.62--4.30)     1.37(0.49--3.81)    1.84(0.64--5.26)     0.360             
  OR [b](#t3-fn2){ref-type="fn"}(95%CI)         1        1.64(0.61--4.41)     1.49(0.51--4.30)    2.28(0.68--7.56)     0.413             
  OR [c](#t3-fn3){ref-type="fn"} (95%CI)        1        1.78(0.60--5.32)     1.76(0.58--5.38)    2.27(0.66--7.88)     0.211          0.280
  25(OH)D below median                                                                                                                   
  No. of cases/no. of controls                54/34           20/16                29/28               26/28                             
  OR[a](#t3-fn1){ref-type="fn"}(95%CI)          1        0.82(0.36--1.86)     0.65(0.32--1.30)    0.60(0.29--1.21)     0.163             
  OR [b](#t3-fn2){ref-type="fn"}(95%CI)         1        0.81(0.35--1.91)     0.66(0.33--1.35)    0.65(0.31--1.35)     0.197             
  OR [c](#t3-fn3){ref-type="fn"} (95%CI)        1        1.17(0.46--2.98)     0.79(0.37--1.66)    0.72(0.33--1.57)     0.490             
  Total 25(OH)D, range (ng/ml)               \<7.29      7.29 -- \<14.61      14.61 -- \<28.84         ≥28.84                            
  VDBP above median                                                                                                                      
  No. of cases/no. of controls                25/31           30/25                18/23               27/27                             
  OR[a](#t3-fn1){ref-type="fn"}(95%CI)          1        1.41(0.65--3.08)     1.17(0.47--2.93)    1.24(0.55--2.78)     0.873             
  OR [b](#t3-fn2){ref-type="fn"}(95%CI)         1        1.42(0.65--3.12)     1.04(0.41--2.66)    1.27(0.55--2.94)     0.946             
  OR [c](#t3-fn3){ref-type="fn"} (95%CI)        1        1.96(0.80--4.79)     1.38(0.48--3.95)    1.67(0.68--4.13)     0.624          0.001
  VDBP below median                                                                                                                      
  No. of cases/no. of controls                55/22           19/28                28/30               10/26                             
  OR[a](#t3-fn1){ref-type="fn"}(95%CI)          1        0.29(0.13--0.64)     0.36(0.17--0.75)    0.15(0.06--0.39)    \<0.001            
  OR [b](#t3-fn2){ref-type="fn"}(95%CI)         1        0.30(0.13--0.69)     0.35(0.16--0.77)    0.13(0.05--0.35)    \<0.001            
  OR [c](#t3-fn3){ref-type="fn"} (95%CI)        1        0.31(0.14--0.71)     0.37(0.16--0.86)    0.14(0.05--0.41)    \<0.001            
  Free 25(OH)D, range (ng/ml)               \<0.0136    0.0136 -- \<0.0329   0.0329 -- \<0.062         ≥0.062                            
  VDBP above median                                                                                                                      
  No. of cases/no. of controls                22/33           45/37                21/22               12/14                             
  OR[a](#t3-fn1){ref-type="fn"}(95%CI)          1        1.56(0.82--2.97)     1.46(0.76--2.83)    1.76(0.86--3.61)     0.477             
  OR [b](#t3-fn2){ref-type="fn"}(95%CI)         1        1.47(0.76--2.85)     1.63(0.77--3.46)    2.13(0.87--5.24)     0.492          0.001
  VDBP below median                                                                                                                      
  No. of cases/no. of controls                36/20           37/16                28/31               11/39                             
  OR[a](#t3-fn1){ref-type="fn"}(95%CI)          1        1.32(0.66--2.65)     0.44(0.23--0.84)    0.12(0.06--0.25)    \<0.001            
  OR [b](#t3-fn2){ref-type="fn"}(95%CI)         1        1.59(0.76--3.33)     0.49(0.25--0.97)    0.10(0.04--0.22)    \<0.001            
  Bioavailable 25(OH)D, range (ng/ml)        \<0.88       0.88 -- \<2.02       2.02 -- \<3.69          ≥3.69                             
  VDBP above median                                                                                                                      
  No. of cases/no. of controls                31/40           29/30                31/24                9/12                             
  OR[a](#t3-fn1){ref-type="fn"}(95%CI)          1        1.10(0.59--2.05)     1.62(0.91--2.88)    1.14(0.58--2.22)     0.541             
  OR [b](#t3-fn2){ref-type="fn"}(95%CI)         1        1.05(0.55--2.00)     1.60(0.84--3.03)    1.13(0.52--2.47)     0.647          0.001
  VDBP below median                                                                                                                      
  No. of cases/no. of controls                42/13           30/23                29/29               11/41                             
  OR[a](#t3-fn1){ref-type="fn"}(95%CI)          1        0.41(0.20--0.85)     0.27(0.13--0.56)    0.04(0.02--0.10)    \<0.001            
  OR [b](#t3-fn2){ref-type="fn"}(95%CI)         1        0.50(0.23--1.09)     0.35(0.16--0.77)    0.03(0.01--0.08)    \<0.001            

^a^Conditioned on age and gender.

^b^Condition on age and gender, and adjusted for BMI, smoking, drinking, history of diabetes and hypertension.

^c^Condition on age and gender, and adjusted for BMI, smoking, drinking, history of diabetes and hypertension as well as either total 25(OH)D or VDBP.

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; OR, odds ratio; VDBP, vitamin D binding protein.
